13 Multiple Myeloma Clinical Trials in Irvine, KY (2026)

Q: How do I join a clinical trial in Irvine?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Irvine research site will contact you.

Recruiting Multiple Myeloma Studies in Irvine

NCT05552222Recruiting

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) ...

Irvine, KY1,590 participantsJanssen Research & Development, LLC

View Study Details

NCT07225738Recruiting

A Multicenter Prospective Observational Cohort Study Evaluating the Impact of Cancer-Directed Treatment and Medication Use, Including Cannabis Use, in Multiple Myeloma Patients

This study assesses the impact of cannabis (also commonly called marijuana, weed, or THC) use on quality of life among patients with multiple myeloma who are receiving chemotherapy. It also evaluates ...

Irvine, KY700 participantsCity of Hope Medical Center

View Study Details

NCT06152575Recruiting

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer). This study is s...

Irvine, KY492 participantsPfizer

View Study Details

NCT07403721Recruiting

AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors

The primary objectives of this trial are to evaluate the safety profile of AMG 436 and to determine the maximum tolerated dose (MTD) and/or the recommended dose for AMG 436 as monotherapy and in combi...

Irvine, KY464 participantsAmgen

View Study Details

NCT07555938Recruiting

Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

The purpose of this study is to assess the efficacy and safety of cevostamab in combination with pomalidomide and dexamethasone (CevosPd) versus standard of care (SOC) in participants with multiple my...

Irvine, KY380 participantsHoffmann-La Roche

View Study Details

NCT04973605Recruiting

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

The purpose of this study is to assess the safety, tolerability, and efficacy of sonrotoclax as monotherapy and in various combinations in patients with relapsed/refractory (R/R) multiple myeloma (MM)...

Irvine, KY246 participantsBeiGene

View Study Details

NCT06455449Recruiting

A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)

The purpose of this multicenter, randomized, placebo-controlled and double-blind study is to evaluate the efficacy and safety of subcutaneous anifrolumab compared with placebo on the overall disease a...

Irvine, KY240 participantsAstraZeneca

View Study Details

NCT06106945Recruiting

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma

This is a Phase I/II, modular, open-label, multicenter, dose escalation, and dose expansion/optimization study to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and prelimina...

Irvine, KY226 participantsAstraZeneca

View Study Details

NCT05652335Recruiting

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

The primary purpose of this study is to identify the recommended phase 2 dose (RP2D\[s\]) and schedule(s) to be safe for JNJ-79635322 in Part 1 (dose escalation), and to characterize the safety and to...

Irvine, KY180 participantsJanssen Research & Development, LLC

View Study Details

NCT07266441Recruiting

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to evaluate how well JNJ-79635322 works (efficacy) in participants with Relapsed or Refractory Multiple Myeloma (RRMM; a cancer that forms in a type of white blood cells c...

Irvine, KY157 participantsJanssen Research & Development, LLC

View Study Details

NCT07409246Recruiting

A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)

Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety, tolerability, and how ABBV-438 ...

Irvine, KY127 participantsAbbVie

View Study Details

NCT06057402Recruiting

Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical benefit from elranatamab monotherapy in the Pfizer-sponsored elranatamab...

Irvine, KY80 participantsPfizer

View Study Details

NCT05551793Recruiting

Regeneron AA Multicenter (Dupilumab)

This is a prospective, randomized, double blind, placebo-controlled clinical trial. The study will take place at 4 sites. This trial will enroll a total of 68 patients with moderate to severe AA (affe...

Irvine, KY76 participantsEmma Guttman

View Study Details

About Multiple Myeloma Clinical Trials in Irvine

Multiple myeloma is a cancer of plasma cells in the bone marrow that produce abnormal antibodies. It can cause bone damage, kidney problems, and immune deficiency. Treatments have advanced significantly with proteasome inhibitors, immunomodulatory drugs, and CAR-T cell therapy.

There are currently 13 multiple myeloma clinical trials recruiting participants in Irvine, KY. These studies are seeking a combined 4,958 participants. Research is being sponsored by Janssen Research & Development, LLC, City of Hope Medical Center, Pfizer and 6 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Multiple Myeloma Clinical Trials in Irvine — FAQ

Are there multiple myeloma clinical trials in Irvine?

Yes, there are 13 multiple myeloma clinical trials currently recruiting in Irvine, KY. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Irvine?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Irvine research site will contact you about next steps.

Are clinical trials in Irvine free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Irvine studies also compensate for your time and travel.

What multiple myeloma treatments are being tested?

The 13 active trials in Irvine are testing new therapies including novel drugs, biologics, and treatment approaches for multiple myeloma.

Data updated July 13, 2026 from ClinicalTrials.gov